{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:08:31Z","timestamp":1788833311174,"version":"build-2803163510"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Accurate diagnosis of Lyme disease, caused by\n                      <jats:italic toggle=\"yes\">Borrelia burgdorferi<\/jats:italic>\n                      , is essential for timely treatment and prevention of long-term complications. This study investigates discrepancies in widely used serological assays and their impact on diagnostic sensitivity in high-risk populations. We analyzed samples from an annual Lyme screening program conducted by Innatoss Laboratories between November 2020 and May 2022, targeting individuals with occupational exposure to ticks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort of 60 positive serum samples from 57 participants (aged 23\u201364) was evaluated using three tier one protocols: EUROIMMUN\/ZEUS enzyme-linked immunosorbent assay (ELISA), SERION ELISA, and Diasorin chemiluminescence immunoassay, followed by Viramed immunoblots for confirmation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our findings revealed significant variability in test sensitivity: the EUROIMMUN\/ZEUS protocol detected 96.8% of cases, compared to 84.1% for SERION (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.023) and 69.8.0% for Diasorin (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Notably, six recent\n                      <jats:italic toggle=\"yes\">Borrelia<\/jats:italic>\n                      infections were missed due to test selection, as confirmed by longitudinal comparison with previous samples. One case study illustrated the clinical consequences of missed diagnoses, including delayed treatment and symptom persistence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These results underscore the need for standardized serological protocols and routine longitudinal sample comparison. We propose the establishment of a consensus panel to define assay performance criteria and recommend integration of electronic health records with laboratory systems to enable automated historical data retrieval. Adoption of more sensitive testing strategies and harmonized interpretation guidelines could significantly improve diagnostic accuracy and patient outcomes in Lyme disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10815589261483668","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:53:31Z","timestamp":1787374411000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Discrepancies in widely used serological methods to detect\n                    <i>Borrelia<\/i>\n                    infections may cause missed Lyme diagnoses"],"prefix":"10.1177","author":[{"given":"Elena","family":"Volokhina","sequence":"first","affiliation":[{"name":"Innatoss Laboratories B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Stemerding","sequence":"additional","affiliation":[{"name":"Deventer Hospital, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesper","family":"Smits","sequence":"additional","affiliation":[{"name":"Innatoss Laboratories B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Lankhof","sequence":"additional","affiliation":[{"name":"Innatoss Laboratories B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou","family":"Kouwijzer","sequence":"additional","affiliation":[{"name":"Innatoss Laboratories B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Garritsen","sequence":"additional","affiliation":[{"name":"Innatoss Laboratories B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Marques AR Strle F Wormser GP. Comparison of Lyme disease in the United States and Europe. Emerg Infect Dis 2021; 27(8): 2017\u20132024. https:\/\/doi.org\/10.3201\/eid2708.204763","DOI":"10.3201\/eid2708.204763"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Steere AC Strle F Wormser GP et al. Lyme borreliosis. Nat Rev Dis Primers 2016; 2(1): 16090. https:\/\/doi.org\/10.1038\/nrdp.2016.90","DOI":"10.1038\/nrdp.2016.90"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Burn L Pilz A Vyse A et al. Seroprevalence of Lyme Borreliosis in Europe: Results from a systematic literature review (2005-2020). Vector Borne Zoonotic Dis 2023; 23(4): 195\u2013220. https:\/\/doi.org\/10.1089\/vbz.2022.0069","DOI":"10.1089\/vbz.2022.0069"},{"key":"e_1_3_3_5_2","volume-title":"Achtergronddocument Bij registratierichtlijn C005 Ziekte van Lyme als beroepsziekte, CAS-code A432","author":"Maas J","year":"2016","unstructured":"Maas J, Gassner F, Frings-Dresen M, et al. Achtergronddocument Bij registratierichtlijn C005 Ziekte van Lyme als beroepsziekte, CAS-code A432. Nederlands Centrum voor Beroepsziekten [Netherlands Center for Occupational Diseases (NCvB)]; 2016."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Stanek G Strle F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev 2018; 42(3): 233\u2013258. https:\/\/doi.org\/10.1093\/femsre\/fux047","DOI":"10.1093\/femsre\/fux047"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Pavia CS Saggio G Plummer MM. The major epidemiologic microbiologic immunologic and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use. Front Immunol 2023; 14: 1326623. https:\/\/doi.org\/10.3389\/fimmu.2023.1326623","DOI":"10.3389\/fimmu.2023.1326623"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Hatchette TF Davis I Johnston BL. Lyme disease: clinical diagnosis and treatment. Can Commun Dis Rep 2014; 40(11): 194\u2013208. https:\/\/doi.org\/10.14745\/ccdr.v40i11a01","DOI":"10.14745\/ccdr.v40i11a01"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Branda JA Steere AC. Laboratory diagnosis of Lyme borreliosis. Clin Microbiol Rev 2021; 34(2). https:\/\/doi.org\/10.1128\/CMR.00018-19","DOI":"10.1128\/CMR.00018-19"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-07110-2"},{"issue":"31","key":"e_1_3_3_11_2","first-page":"590","article-title":"Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease","volume":"44","author":"Centers for Disease Control and Prevention (CDC)","year":"1995","unstructured":"Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44(31): 590\u2013591.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Baarsma ME Vrijlandt A Ursinus J et al. Diagnostic performance of the ZEUS Borrelia VlsE1\/pepC10 assay in European LB patients: a case-control study. Eur J Clin Microbiol Infect Dis 2022; 41(3): 387\u2013393. https:\/\/doi.org\/10.1007\/s10096-021-04372-6","DOI":"10.1007\/s10096-021-04372-6"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Eicken C Sharma V Klabunde T et al. Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. J Biol Chem 2002; 277(24): 21691\u201321696. https:\/\/doi.org\/10.1074\/jbc.M201547200","DOI":"10.1074\/jbc.M201547200"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Wozinska M Toczylowski K Lewandowski D et al. Diagnostic precision in Lyme borreliosis: assessing VlsE and C6 antigens in a pediatric cohort. Diagnostics (Basel) 2023; 13(23): 3547. https:\/\/doi.org\/10.3390\/diagnostics13233547","DOI":"10.3390\/diagnostics13233547"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Hoeve-Bakker BJA van den Berg OE Doppenberg HS et al. Seroprevalence and risk factors of Lyme borreliosis in the Netherlands: a population-based cross-sectional study. Microorganisms 2023; 11(4): 1081. https:\/\/doi.org\/10.3390\/microorganisms11041081","DOI":"10.3390\/microorganisms11041081"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Leeflang MM Ang CW Berkhout J et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis 2016; 16: 140. https:\/\/doi.org\/10.1186\/s12879-016-1468-4","DOI":"10.1186\/s12879-016-1468-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Hoeve-Bakker BJA Jonker M Brandenburg AH et al. The performance of nine commercial serological screening assays for the diagnosis of Lyme borreliosis: a multicenter modified two-gate design study. Microbiol Spectr 2022; 10(2): e0051022. https:\/\/doi.org\/10.1128\/spectrum.00510-22","DOI":"10.1128\/spectrum.00510-22"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Lager M Dessau RB Wilhelmsson P et al. Serological diagnostics of Lyme borreliosis: comparison of assays in twelve clinical laboratories in Northern Europe. Eur J Clin Microbiol Infect Dis 2019; 38(10): 1933\u20131945. https:\/\/doi.org\/10.1007\/s10096-019-03631-x","DOI":"10.1007\/s10096-019-03631-x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Baarsma ME van de Schoor FR Gauw SA et al. Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study. Lancet Infect Dis 2022; 22(9): 1388\u20131396. https:\/\/doi.org\/10.1016\/S1473-3099(22)00205-5","DOI":"10.1016\/S1473-3099(22)00205-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Pritt BS Mead PS Johnson DKH et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis 2016; 16(5): 556\u2013564. https:\/\/doi.org\/10.1016\/S1473-3099(15)00464-8","DOI":"10.1016\/S1473-3099(15)00464-8"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Magni R Almofee R Yusuf S et al. Evaluation of pathogen specific urinary peptides in tick-borne illnesses. Sci Rep 2020; 10(1): 19340. https:\/\/doi.org\/10.1038\/s41598-020-75051-3","DOI":"10.1038\/s41598-020-75051-3"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Shan J Jia Y Teuli\u00e8res L et al. Targeting multicopy prophage genes for the increased detection of Borrelia burgdorferi Sensu Lato (s.l.) the causative agents of lyme disease in blood. Front Microbiol 2021; 12: 651217. https:\/\/doi.org\/10.3389\/fmicb.2021.651217","DOI":"10.3389\/fmicb.2021.651217"},{"key":"e_1_3_3_23_2","unstructured":"Certification documents for external quality assesment of infection serology- Borrelia burgdorferi antibodies (332) held in March 2024. INSTAND; 2024."},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Infantino M Pieri M Nuccetelli M et al. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol 2021; 100: 108095. https:\/\/doi.org\/10.1016\/j.intimp.2021.108095","DOI":"10.1016\/j.intimp.2021.108095"},{"key":"e_1_3_3_25_2","unstructured":"World Health Organization. International collaborative study to evaluate and establish the 1st WHO reference reagent for anti-Q fever Phases I and II IgG human plasma. WHO\/BS\/2023.2456; 2023."},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Gr\u0105\u017alewska W Ferra B Rudzi\u0144ska M et al. BmpA-BBK32 and BmpA-BBA64: new recombinant chimeric proteins with potential diagnostic value. Pathogens 2021; 10(6): 767. https:\/\/doi.org\/10.3390\/pathogens10060767","DOI":"10.3390\/pathogens10060767"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261483668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589261483668","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261483668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:47:12Z","timestamp":1788832032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589261483668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":25,"alternative-id":["10.1177\/10815589261483668"],"URL":"https:\/\/doi.org\/10.1177\/10815589261483668","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"10815589261483668"}}